Radiopharm Theranostics Limited (RADX)

Market Cap	35.71M
Revenue (ttm)	1.31M
Net Income (ttm)	-31.99M
Shares Out	2.17B
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,900
Open	4.960
Previous Close	4.661
Day's Range	4.590 - 4.970
52-Week Range	3.550 - 50.820
Beta	0.85
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 26, 2025

About RADX

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: NASDAQ
• Ticker Symbol: RADX

Financial Performance

In 2024, Radiopharm Theranostics's revenue was 1.96 million, a decrease of -68.46% compared to the previous year's 6.21 million. Losses were -47.95 million, 38.5% more than in 2023.

Financial numbers in AUD